Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 13/20 | 1.00 |
| ▸ | GRM5 | P41594 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858877 | 1.00 | SORT1 (1.00) | SORT1GRM5ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29980945 | 0.89 | SORT1 (1.00) | SORT1GRM5ALDH1A1 | |
| SCHEMBL15903152 | 0.89 | SORT1 (1.00) | SORT1GRM5ALDH1A1 | |
| SCHEMBL15903421 | 0.86 | SORT1 (1.00) | SORT1GRM5 | |
| SCHEMBL29981174 | 0.86 | SORT1 (0.90) | SORT1GRM5ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29858578 | 0.86 | SORT1 (1.00) | SORT1GRM5 | |
| SCHEMBL15903424 | 0.86 | SORT1 (0.90) | SORT1GRM5ALDH1A1HPGDHSD17B10 | |
| SCHEMBL15903724 | 0.85 | SORT1 (1.00) | SORT1 | |
| SCHEMBL23825508 | 0.85 | SORT1 (0.74) | SORT1GRM5ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29980451 | 0.85 | SORT1 (0.74) | SORT1GRM5ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313016-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Sanford Health (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | claimed |
| EP-4225280-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | Insusense ApS (DK) | 2023-08-16 | — | — | EP | claimed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | claimed |
| EP-4121033-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | Insusense ApS (DK) | 2023-01-25 | — | — | EP | claimed |
| CN-115297856-A | Sortilin antagonists for the treatment of diabetic retinopathy | 舒感有限公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022212268-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | SANFORD HEALTH (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022074119-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | INSUSENSE ApS (DK) | 2022-04-14 | — | — | WO | claimed |
| EP-3981394-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS. | Insusense ApS (DK) | 2022-04-13 | — | — | EP | claimed |
| WO-2021186054-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | INSUSENSE ApS (DK) | 2021-09-23 | — | — | WO | claimed |
| EP-3881840-A1 | SORTILIN ANTAGONISTS FOR USE INTHE TREATMENT OF DIABETIC RETINOPATHY | Insusense ApS (DK) | 2021-09-22 | — | — | EP | claimed |
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | claimed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | claimed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | claimed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | claimed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | claimed |
| EP-2948147-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. Lundbeck A/S (DK) | 2015-12-02 | — | — | EP | claimed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | claimed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| EP-4225280-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | Insusense ApS (DK) | 2023-08-16 | — | — | EP | disclosed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| EP-4121033-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | Insusense ApS (DK) | 2023-01-25 | — | — | EP | disclosed |
| CN-115297856-A | Sortilin antagonists for the treatment of diabetic retinopathy | 舒感有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022074119-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | INSUSENSE ApS (DK) | 2022-04-14 | — | — | WO | disclosed |
| EP-3981394-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS. | Insusense ApS (DK) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981394-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS. | Insusense ApS (DK) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021186054-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | INSUSENSE ApS (DK) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186054-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | INSUSENSE ApS (DK) | 2021-09-23 | — | — | WO | disclosed |
| EP-3881840-A1 | SORTILIN ANTAGONISTS FOR USE INTHE TREATMENT OF DIABETIC RETINOPATHY | Insusense ApS (DK) | 2021-09-22 | — | — | EP | disclosed |
| EP-3881840-A1 | SORTILIN ANTAGONISTS FOR USE INTHE TREATMENT OF DIABETIC RETINOPATHY | Insusense ApS (DK) | 2021-09-22 | — | — | EP | disclosed |
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | disclosed |
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | disclosed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | disclosed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| EP-2948147-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. Lundbeck A/S (DK) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | SORT1, NRP1, SELPLG | SORT1 1/4885GRM5 105/4885ALDH1A1 1062/4885 |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | SORT1, SCARB1, NRP1 | SORT1 1/4885GRM5 2182/4885ALDH1A1 1777/4885 |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | SORT1, NRP1, SELPLG | SORT1 1/4885GRM5 99/4885ALDH1A1 1271/4885 |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | SORT1, NRP1, SELPLG | SORT1 1/4885GRM5 99/4885ALDH1A1 1271/4885 |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | SORT1, NTSR2, SLC17A5 | SORT1 1/4885GRM5 1745/4885ALDH1A1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.